GenoFocus Inc
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phy… Read more
GenoFocus Inc (187420) - Net Assets
Latest net assets as of September 2025: ₩44.88 Billion KRW
Based on the latest financial reports, GenoFocus Inc (187420) has net assets worth ₩44.88 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩133.13 Billion) and total liabilities (₩88.25 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩44.88 Billion |
| % of Total Assets | 33.71% |
| Annual Growth Rate | 9.42% |
| 5-Year Change | -40.23% |
| 10-Year Change | -20.2% |
| Growth Volatility | 72.2 |
GenoFocus Inc - Net Assets Trend (2014–2024)
This chart illustrates how GenoFocus Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GenoFocus Inc (2014–2024)
The table below shows the annual net assets of GenoFocus Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩23.77 Billion | -9.83% |
| 2023-12-31 | ₩26.36 Billion | +10.34% |
| 2022-12-31 | ₩23.89 Billion | -32.28% |
| 2021-12-31 | ₩35.28 Billion | -11.29% |
| 2020-12-31 | ₩39.77 Billion | -23.70% |
| 2019-12-31 | ₩52.12 Billion | -13.44% |
| 2018-12-31 | ₩60.21 Billion | -6.24% |
| 2017-12-31 | ₩64.22 Billion | +2.72% |
| 2016-12-31 | ₩62.52 Billion | +109.88% |
| 2015-12-31 | ₩29.79 Billion | +208.31% |
| 2014-12-31 | ₩9.66 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GenoFocus Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5649771435000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩14.57 Billion | 61.29% |
| Other Components | ₩67.81 Billion | 285.27% |
| Total Equity | ₩23.77 Billion | 100.00% |
GenoFocus Inc Competitors by Market Cap
The table below lists competitors of GenoFocus Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Trk Corp
TW:1432
|
$34.47 Million |
|
Vittia Fertilizantes
SA:VITT3
|
$34.48 Million |
|
H&R GmbH & Co. KGaA
XETRA:2HRA
|
$34.48 Million |
|
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
|
$34.48 Million |
|
Cardlytics Inc
NASDAQ:CDLX
|
$34.46 Million |
|
Lotus Bakeries NV
PINK:LOTBY
|
$34.44 Million |
|
Firma Oponiarska DĘBICA SA
WAR:DBC
|
$34.43 Million |
|
ANGLE plc
OTCQX:ANPCF
|
$34.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GenoFocus Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,036,616,830 to 23,769,596,870, a change of 1,732,980,040 (7.9%).
- Net loss of 18,828,066,010 reduced equity.
- Share repurchases of 14,999,981,690 reduced equity.
- New share issuances of 14,999,981,680 increased equity.
- Other factors increased equity by 20,561,046,060.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-18.83 Billion | -79.21% |
| Share Repurchases | ₩15.00 Billion | -63.11% |
| Share Issuances | ₩15.00 Billion | +63.11% |
| Other Changes | ₩20.56 Billion | +86.5% |
| Total Change | ₩- | 7.86% |
Book Value vs Market Value Analysis
This analysis compares GenoFocus Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.86x to 3.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3160.30 | ₩2720.00 | x |
| 2017-12-31 | ₩3222.43 | ₩2720.00 | x |
| 2018-12-31 | ₩2761.55 | ₩2720.00 | x |
| 2019-12-31 | ₩2357.82 | ₩2720.00 | x |
| 2020-12-31 | ₩1775.39 | ₩2720.00 | x |
| 2021-12-31 | ₩1568.01 | ₩2720.00 | x |
| 2022-12-31 | ₩1060.71 | ₩2720.00 | x |
| 2023-12-31 | ₩968.28 | ₩2720.00 | x |
| 2024-12-31 | ₩815.82 | ₩2720.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GenoFocus Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -79.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -53.14%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 6.15x
- Recent ROE (-79.21%) is below the historical average (-16.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 22.58% | 35.48% | 0.36x | 1.75x | ₩1.22 Billion |
| 2015 | 4.07% | 18.24% | 0.22x | 1.02x | ₩-1.77 Billion |
| 2016 | 2.58% | 22.97% | 0.11x | 1.01x | ₩-4.64 Billion |
| 2017 | 2.20% | 12.26% | 0.16x | 1.09x | ₩-5.01 Billion |
| 2018 | -3.85% | -20.11% | 0.16x | 1.17x | ₩-8.34 Billion |
| 2019 | -11.05% | -38.53% | 0.17x | 1.73x | ₩-10.97 Billion |
| 2020 | -30.72% | -65.09% | 0.17x | 2.85x | ₩-16.19 Billion |
| 2021 | -19.32% | -26.35% | 0.22x | 3.36x | ₩-10.34 Billion |
| 2022 | -54.28% | -46.64% | 0.21x | 5.60x | ₩-15.36 Billion |
| 2023 | -13.39% | -10.92% | 0.28x | 4.44x | ₩-5.15 Billion |
| 2024 | -79.21% | -53.14% | 0.24x | 6.15x | ₩-21.21 Billion |
Industry Comparison
This section compares GenoFocus Inc's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $729,340,395,312
- Average return on equity (ROE) among peers: 5.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GenoFocus Inc (187420) | ₩44.88 Billion | 22.58% | 1.97x | $34.47 Million |
| DL Holdings CO. LTD. (000210) | $4.53 Trillion | 19.10% | 0.84x | $381.57 Million |
| Norooholdings (000320) | $402.45 Billion | 6.30% | 1.12x | $45.80 Million |
| Noroo Holdings Co Ltd (000325) | $583.54 Billion | 0.27% | 0.81x | $60.77 Million |
| Samhwa Paint (000390) | $299.72 Billion | 1.87% | 0.96x | $86.24 Million |
| Kangnam Jevisco Co Ltd (000860) | $366.15 Billion | 10.97% | 0.26x | $58.42 Million |
| Paik Kwang Ind (001340) | $204.57 Billion | 3.85% | 1.06x | $113.44 Million |
| Bo Lak (002760) | $43.76 Billion | 2.53% | 0.22x | $30.02 Million |
| Songwon Industrial (004430) | $543.25 Billion | 13.30% | 1.05x | $79.87 Million |
| Cho Kwang Pain (004910) | $172.73 Billion | -1.34% | 0.81x | $17.90 Million |
| Cosmoam&T (005070) | $147.00 Billion | -3.99% | 0.78x | $305.37 Million |